Lepirudin as an alternative to "heparin allergy" during cardiopulmonary bypass

Journal of Cardiothoracic Surgery

Volumn 6, Issue 1, 2011, Pages

  Parissis, Haralabos ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; HEPARIN; HIRUDIN DERIVATIVE; LEPIRUDIN; RECOMBINANT PROTEIN;

ADULT; ARTICLE; CARDIOPULMONARY BYPASS; CASE REPORT; FEMALE; FOLLOW UP; HEART SEPTUM DEFECT; HEART SURGERY; HUMAN; METHODOLOGY; POSTOPERATIVE COMPLICATION; THROMBOSIS;

ADULT; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HEART SEPTAL DEFECTS, ATRIAL; HEPARIN; HIRUDINS; HUMANS; POSTOPERATIVE COMPLICATIONS; RECOMBINANT PROTEINS; THROMBOSIS;

EID: 79953750658     PISSN: None     EISSN: 17498090     Source Type: Journal    
DOI: 10.1186/1749-8090-6-44     Document Type: Article

References (21)

1. Markwardt F. Hirudin: the promising antithrombotic. Cardiovasc Drug Rev 1992, 10:211-232.
2. Gardell SJ, Sanderson PE. Novel anticoagulants based on direct inhibition of thrombin and factor Xa. Coron Artery Dis 1998, 9:75-8 1.
3. Weitz JI, Huboda M, Massel D, Marganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990, 86:385-391.
4. Greinacher A, Völpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P, H G. Mueller-Velten and B. Pötzsch. Recombinant Hirudin (Lepirudin) Provides Safe and Effective Anticoagulation in Patients With Heparin-Induced Thrombocytopenia: A Prospective Study. Circulation 1999, 99:73-80.
5. Greinacher A, Lubenow N. Recombinant hirudin in clinical practice: Focus on lepirudin. Circulation 2001, 103:1479-1484.
6. Pappalardo F, Franco A, Crescenzi G, Poli A, Zangrillo A, Koster A. Successful use of bivalirudin for cardiopulmonary bypass in a patient with heparin allergy. Perfusion 2007, 22:67-69.
7. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003, 121:535-555.
8. Warkentin TE, Hayward CPM, Boshkov LK, Santos AV, Sheppard JI, Bode AP, Kelton JG. Sera from patients heparin-induced thrombocy- topenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin- induced thrombocytopenia. Blood 1994, 84:3691-3699.
9. Walls JT, Curtis JJ, Silver D, Boley TM. Heparin-induced thrombocytopenia in patients who undergo open heart surgery. Surgery 1990, 108:686-693.
10. Weitz JI, Leslie B, Hudoba M. Thrombin binds to soluble -brin degradation products where it is prothrombosed from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin- independent inhibitors. Circulation 1998, 97:544-552.
11. Riess FC. Anticoagulation management and cardiac surgery in patients with heparin-induced thrombocytopenia. Semin Thorac Cardiovasc Surg. Spring 2005, 17(1):85-96.
12. Koster A, Hansen R, Kuppe H, Hetzer R, G J. Crystal, F Mertzlufft. Recombinant Hirudin as an Alternative for Anticoagulation During Cardiopulmonary Bypass in Patients With Heparin-Induced Thrombocytopenia Type II: A 1-Year Experience in 57 Patients. Journal of Cardiothoracic and Vascular Anesthesia 2000, 243-248. Vo114, No 3 (June).
13. Riess FC, Poetzsch B, Madlener K, Cramer E, Doll KN, Doll S, Lorke DE, Kormann J, Mueller-Berghaus G. Recombinant hirudin for cardiopulmonary bypass anticoagulation: a randomized, prospective, and heparin-controlled pilot study. Thorac Cardiovasc Surg 2007, 55(4):233-8.
14. Greinacher A, Vö1pel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia. A prospective study. Circulation 1999, 99:73-80.
15. Greinacher A, Lepirudin. a bivalent direct thrombin inhibitor for anticoagulation therapy. Expert Rev Cardiovasc Ther 2004, 2(3):339-57.
16. Murphy GS, Marymont JH. Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery. J Cardiothorac Vasc Anesth 2007, 21(1):113-26. Epub 2006 Oct 24.
17. Riess FC, Pötzsch B, Bader R, et al. A case report on the use of recombinant hirudin as an anticoagulant for car- diopulmonary bypass in open heart surgery. Eur J Cardiothorac Surg 1996, 10:386-8.
18. Longrois D, de Maistre E, Bischoff N, Dopff C, Meistelman C, Angioï M, Lecompte T. Recombinant hirudin anticoagulation for aortic valve replacement in heparin-induced thrombocytopenia. Can J Anaesth 2000, 47(3):255-60.
19. Song X, Huhle G, Wang L, et al. Generation of anti-himdin antibodies in heparin-induced thrombocytopenia patients treated with r-hirudin. Circulation 1999, 5:1528-1532.
20. Dyke CM, Smedira NG, Koster A, Aronson S, McCarthy HL, Kirshner R, Lincoff AM, Spiess BD. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg 2006, 131(3):533-9.
21. Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 2003, 108:2062-65.